Covilife 40 mg

When the dose matches a confirmed susceptible infection, Covilife 40 mg can:

• Act against susceptible parasites

• Help clear intestinal strongyloidiasis

• Reduce microfilariae in onchocerciasis

• Control scabies mite activity

• Relieve parasite-related skin symptoms

• Support recovery from diagnosed infections

The medicine does not work against every worm or skin condition. Its benefits depend on correct diagnosis and an accurately calculated dose.

Ivermectin attaches to glutamate-gated chloride channels in the nerve and muscle cells of susceptible parasites. This increases chloride movement into the cells and interrupts normal nerve signals.

The parasites become paralysed and die or lose their ability to remain in the body. The body then removes them naturally.

Cancer researchers are separately examining ivermectin’s effects on tumour-cell signalling and immune responses. These experimental actions have not established Covilife 40 mg as a cancer medicine.

Oral ivermectin is dosed according to body weight and the diagnosed infection. The 40 mg printed on the pack describes the amount in each tablet. It is not a universal dose.

For strongyloidiasis, ivermectin is commonly prescribed at approximately 200 micrograms per kilogram of body weight as a single dose. For onchocerciasis, the calculated dose is commonly around 150 micrograms per kilogram. Scabies follows a different schedule and often requires a repeat dose after a defined interval.

Covilife 40 mg should be used only when this tablet strength matches the calculated total dose. Do not assume that one complete tablet is suitable for every infection or adult.

Swallow the instructed amount with water on an empty stomach. Do not divide the tablet unless it is designed for splitting and the required amount has been confirmed. Persistent itching does not automatically mean that another dose is needed.

There is no established Covilife 40 mg dosage for COVID-19 or cancer. Do not copy online protocols or doses used in clinical trials.

Common Side Effects: Covilife 40 mg can cause nausea, diarrhoea, abdominal discomfort, dizziness, headache, tiredness, itching or a skin rash. Some symptoms result from the body’s inflammatory response to dying parasites. Contact a healthcare professional if these effects persist or become troublesome.

Serious Side Effects: Seek urgent medical attention for breathing difficulty, facial swelling, fainting, severe blistering skin reactions, confusion, seizures, difficulty walking, extreme drowsiness, vision changes or yellowing of the skin or eyes. People with a heavy Loa loa infection can develop a serious neurological reaction after ivermectin treatment.

Covilife 40 mg should be avoided or used only after professional assessment by:

• People allergic to ivermectin

• Children weighing under 15 kg

• Pregnant or breastfeeding women

• People with severe liver disease

• People with suspected Loa loa infection

• People taking warfarin

• People using interacting medicines

• People seeking COVID-19 self-treatment

• People seeking cancer self-treatment

Tell the healthcare professional about all medicines, supplements and herbal products being used.

Important interactions include:

• Warfarin and other anticoagulants

• Azole antifungal medicines

• Macrolide antibiotics

• HIV protease inhibitors

• Anti-seizure medicines

• Sedating medicines

• Other antiparasitic medicines

• Chemotherapy or immunotherapy

Do not combine Covilife with another ivermectin product or experimental treatment without professional review.

• Keep the tablets in their original packaging.

• Store them in a cool and dry place.

• Protect the pack from moisture and sunlight.

• Keep it away from children and pets.

• Do not use damaged or discoloured tablets.

• Check the expiry date before use.